COL18A1 as the candidate gene for the prognostic marker of breast cancer according to the analysis of the DNA copy number variation by array CGH

Journal of Breast Cancer

Volumn 13, Issue 1, 2010, Pages 37-45

  Hwang, Ki Tae ^a   Chung, Jung Kee ^a   Jung, In Mok ^a   Heo, Seung Chul ^a   Ahn, Young Joon ^a   Ahn, Hye Seong ^a   Chang, Mee Soo ^a   Kim, Jeong Ah ^b   Han, Wonshik ^b   Noh, Dong Young ^b  

^a Seoul National University Boramae Hospital   (South Korea)

^b Seoul National University   (South Korea)

Author keywords

Breast neoplasms; Collagen type xviii; Gene amplification; Microarray analysis

Indexed keywords

BIOLOGICAL MARKER; PROTEIN COL18A1; RNA; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER PATIENT; CHROMOSOME 14Q; CHROMOSOME 15Q; CHROMOSOME 17Q; CHROMOSOME 1Q; CHROMOSOME 21Q; CHROMOSOME 5P; CHROMOSOME 8Q; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; COPY NUMBER VARIATION; DISEASE MARKER; FEMALE; GENE EXPRESSION; GENE IDENTIFICATION; GENE LOSS; GENE OVEREXPRESSION; GENETIC GAIN; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MICROARRAY ANALYSIS; MOLECULAR CLONING; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL; UPREGULATION; VALIDATION STUDY;

EID: 77953181227     PISSN: 17386756     EISSN: None     Source Type: Journal    
DOI: 10.4048/jbc.2010.13.1.37     Document Type: Article

References (28)

1. Sotiriou C, Piccart MJ. Taking gene-expression profiling to the clinic: when will molecular signatures become relevant to patient care? Nat Rev Cancer 2007;7:545-53.
2. Tan DS, Reis-Filho JS. Comparative genomic hybridisation arrays: high-throughput tools to determine targeted therapy in breast cancer. Pathobiology 2008;75:63-74.
3. Davies JJ, Wilson IM, Lam WL. Array CGH technologies and their applications to cancer genomes. Chromosome Res 2005;13:237-48.
4. van Beers EH, Nederlof PM. Array-CGH and breast cancer. Breast Cancer Res 2006;8:210.
5. Hwang KT, Han W, Cho J, Lee JW, Ko E, Kim EK, et al. Genomic copy number alterations as predictive markers of systemic recurrence in breast cancer. Int J Cancer 2008;123:1807-15.
6. Chebil G, Bendahl PO, Fernö M; South Sweden Breast Cancer Group; North Sweden Breast Cancer Group. Estrogen and progesterone receptor assay in paraffin-embedded breast cancer-reproducibility of assessment. Acta Oncol 2003;42:43-7.
7. Kim HS, Jung JH, Park HY, Lee YH, Chung EJ, Kim MK, et al. Gene expression profile analysis of human breast cancer using cDNA microarrys. J Korean Breast Cancer Soc 2003;6:58-67.
8. Han W, Chung KW, Ahn SJ, Noh DY, Youn YK, Oh SK, et al. Gene expression profiles of primary breast cancer tissue using cDNA microarray. J Korean Breast Cancer Soc 2002;5:284-90.
9. Kim MY, Yim SH, Kwon MS, Kim TM, Shin SH, Kang HM, et al. Recurrent genomic alterations with impact on survival in colorectal cancer identified by genome-wide array comparative genomic hybridization. Gastroenterology 2006;131:1913-24.
10. Thomassen M, Tan Q, Kruse TA. Gene expression meta-analysis identifies chromosomal regions and candidate genes involved in breast cancer metastasis. Breast Cancer Res Treat 2009;113:239-49.
11. Nakatani K, Thompson DA, Barthel A, Sakaue H, Liu W, Weigel RJ, et al. Up-regulation of Akt3 in estrogen receptor-deficient breast cancers and androgen-independent prostate cancer lines. J Biol Chem 1999;274:21528-32.
12. Liu D, Rudland PS, Sibson DR, Barraclough R. Identification of mRNAs differentially-expressed between benign and malignant breast tumour cells. Br J Cancer 2002;87:423-31.
13. Han W, Han MR, Kang JJ, Bae JY, Lee JH, Bae YJ, et al. Genomic alterations identified by array comparative genomic hybridization as prognostic markers in tamoxifen-treated estrogen receptor-positive breast cancer. BMC Cancer 2006;6:92.
14. Naylor TL, Greshock J, Wang Y, Colligon T, Yu QC, Clemmer V, et al. High resolution genomic analysis of sporadic breast cancer using array-based comparative genomic hybridization. Breast Cancer Res 2005;7:R1186-98.
15. Nessling M, Richter K, Schwaenen C, Roerig P, Wrobel G, Wessendorf S, et al. Candidate genes in breast cancer revealed by microarraybased comparative genomic hybridization of archived tissue. Cancer Res 2005;65:439-47.
16. Rennstam K, Ahlstedt-Soini M, Baldetorp B, Bendahl PO, Borg A, Karhu R, et al. Patterns of chromosomal imbalances defines subgroups of breast cancer with distinct clinical features and prognosis. A study of 305 tumors by comparative genomic hybridization. Cancer Res 2003;63:8861-8.
17. Dang C, Zhang Y, Ma Q, Shimahara Y. Expression of nerve growth factor receptors is correlated with progression and prognosis of human pancreatic cancer. J Gastroenterol Hepatol 2006;21:850-8.
18. Brzeziańska E, Karbownik M, Migdalska-Sek M, Pastuszak-Lewandoska D, Wloch J, Lewiński A. Molecular analysis of the RET and NTRK1 gene rearrangements in papillary thyroid carcinoma in the Polish population. Molecular analysis of the RET and NTRK1 gene rearrangements in papillary thyroid carcinoma in the Polish population. Mutat Res 2006;599:26-35.
19. Tokusashi Y, Asai K, Tamakawa S, Yamamoto M, Yoshie M, Yaginuma Y, et al. Expression of NGF in hepatocellular carcinoma cells with its receptors in non-tumor cell components. Int J Cancer 2005; 114:39-45.
20. Iizasa T, Chang H, Suzuki M, Otsuji M, Yokoi S, Chiyo M, et al. Overexpression of collagen XVIII is associated with poor outcome and elevated levels of circulating serum endostatin in non-small cell lung cancer. Clin Cancer Res 2004;10:5361-6.
21. Swidzińska E, Ossolińska M, Naumnik W, Trojan S, Chyczewska E. Serum endostatin levels in patients with lung carcinoma. Rocz Akad Med Bialymst 2005;50:197-200.
22. Woo IS, Kim KA, Jeon HM, Hong SH, Rho SY, Koh SJ, et al. Pretreatment serum endostatin as a prognostic indicator in metastatic gastric carcinoma. Int J Cancer 2006;119:2901-6.
23. Kikuchi E, Menendez S, Ohori M, Cordon-Cardo C, Kasahara N, Bochner BH. Inhibition of orthotopic human bladder tumor growth by lentiviral gene transfer of endostatin. Clin Cancer Res 2004;10: 1835-42.
24. Hu TH, Huang CC, Wu CL, Lin PR, Liu SY, Lin JW, et al. Increased endostatin/collagen XVIII expression correlates with elevated VEGF level and poor prognosis in hepatocellular carcinoma. Mod Pathol 2005;18:663-72.
25. Balasubramanian SP, Cross SS, Globe J, Cox A, Brown NJ, Reed MW. Endostatin gene variation and protein levels in breast cancer susceptibility and severity. BMC Cancer 2007;7:107.
26. Beck MT, Chen NY, Franek KJ, Chen WY. Prolactin antagonistendostatin fusion protein as a targeted dual-functional therapeutic agent for breast cancer. Cancer Res 2003;63:3598-604.
27. Lourenço GJ, Cardoso-Filho C, Gonçales NS, Shinzato JY, Zeferino LC, Nascimento H, et al. A high risk of occurrence of sporadic breast cancer in individuals with the 104NN polymorphism of the COL18A1 gene. Breast Cancer Res Treat 2006;100:335-8.
28. Chari R, Lockwood WW, Lam WL. Computational methods for the analysis of array comparative genomic hybridization. Cancer Inform 2007;2:48-58.